Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Palbociclib,PALB2023-001,2023,USA,MDV,350,62,99,1,27.5,18,85,5,15,40,30,15,55,30,10,5,20,45,30,12,3,2,5,1,8,45,35,AC,TC,CMF,Taxol,25,35,30,20,40,30,15,50,35,60,2
Palbociclib,PALB2022-002,2022,Canada,Claim Database,420,68,98,2,28.1,22,78,7,12,38,32,18,52,33,11,4,18,42,33,15,4,3,7,2,10,48,38,EC,AC-T,FEC,Docetaxel,28,32,33,22,42,32,12,48,40,65,3
Palbociclib,PALB2024-003,2024,UK,MDV,280,65,97,3,26.9,20,80,6,14,42,28,16,54,31,9,6,19,44,29,13,3.5,2.5,6,1.5,9,46,36,FEC-T,Docetaxel/Carboplatin,EC,CMF,26,34,31,21,41,31,14,49,37,62,2.5
Palbociclib,PALB2023-004,2023,Australia,Claim Database,380,63,98.5,1.5,29.0,15,82,4,16,39,29,16,56,29,12,3,21,43,28,11,2.5,1.5,4,0.5,7,44,34,AC,Taxol/Herceptin,CMF,FEC,24,36,29,19,39,29,16,51,33,58,1.5
